RAC 2.20% $1.78 race oncology ltd

RAC - Crystal ball gazing, page-39

  1. 2,805 Posts.
    lightbulb Created with Sketch. 2469
    I don’t think re-engaging Triangle is going to change anything.

    I think having Triangle update their valuation based on milestones that derisk the commericalisation of Bisantrene is important. Given the majority of the register is retail, they need educating to what is fair value. When the commercialisation finally arrives they will have an idea of what is good value.

    Cheers
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.